Return to Colorectal Cancer Specialty Channel

Colorectal Cancer Newswatch

The FDA has approved a higher dose of cetuximab for the treatmen of patients with KRAS wild-type, EGFR-expressing metastatic colorectal cancer or squamous cell carcinoma of the head and neck.
Anlotinib was beneficial in Chinese patients with refractory metastatic CRC, and yielded particular OS improvement in those with RAS/KRAS/BRAF-wildtype disease.
Findings from a cohort study of patients with advanced or metastatic CRC showed that increased coffee consumption was linked to a lower risk for disease progression and death.
Julio Garcia-Aguilar, MD, PhD, provided insight on how nonoperative management of rectal cancer is evolving at the virtual 2020 Great Debates & Updates in Gastrointestinal Malignancies meeting.
An international study has shown that patients with colon cancer and a higher Immunoscore benefit the most from chemo in terms of recurrence risk.
At the virtual 2020 Great Debates and Updates in GI Malignancies, experts in the oncology space will discuss and debate advancements in therapies for GI cancers.
Carboplatin plus paclitaxel should be considered as a new standard of care for advanced anal cancer, results from an international phase 2 trial suggest.
The 2-stage pull-through hand-sewn coloanal anastomosis is safe for use in patients with low rectal cancer who have undergone resection.
Stay in the know.
OncNet Newsletter